Form 4: Revolution Medicines CMO Sells Shares to Cover Tax Obligations

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,173 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, as part of a pre-arranged Rule 10b5-1 plan to cover tax withholding from RSU vesting.

Summary

• Wei Lin, the Chief Medical Officer of Revolution Medicines, Inc. (RVMD), reported the sale of 2,173 shares of the company's common stock.
• The transaction took place on June 16, 2025.
• The shares were sold at a weighted average price of $39.83 per share, with individual trades ranging from $39.6017 to $39.8291.
• This sale was conducted pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024.
• The primary purpose of the sale was to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025.
• Following this transaction, Wei Lin beneficially owns 90,499 shares of common stock.
• This beneficial ownership includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025, and 64,800 Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The transaction is a pre-scheduled sale under a Rule 10b5-1 plan to cover tax obligations from RSU vesting, which is a common and expected event for executives receiving equity compensation. It does not indicate a change in management's view of the company's prospects and is therefore neutral to slightly positive due to the planned nature.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 plan, indicating it was a scheduled, non-discretionary transaction for tax purposes rather than a sale based on new negative information.
• The Chief Medical Officer continues to hold a significant number of shares (90,499) and RSUs (64,800) in the company, demonstrating continued alignment with shareholder interests.
• The reporting person also acquired additional shares (1,021) through the company's Employee Stock Purchase Plan, indicating ongoing participation in company equity programs.

Negatives

• Any insider selling, even for tax purposes, can sometimes be perceived negatively by some market participants, although this is a common and expected event for executives receiving equity compensation.

Future Outlook

This SEC Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This transaction is a routine insider stock sale, common across all industries, particularly for executives who receive equity compensation in the form of restricted stock units. Such sales are often pre-arranged under Rule 10b5-1 plans to manage tax obligations upon vesting, and do not typically reflect a change in the company's operational or strategic direction.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of ownership, but it is a routine event for tax purposes and not indicative of a lack of confidence from the insider. The pre-arranged nature under a 10b5-1 plan mitigates concerns.
• Employees: The Chief Medical Officer, as an employee, is directly impacted by the tax obligations arising from RSU vesting, which this sale addresses.

Key Dates

Recommendation

Keywords

Revolution Medicines, RVMD, Wei Lin, Form 4, Insider Trading, Stock Sale, Chief Medical Officer, RSU Vesting, 10b5-1 Plan, Employee Stock Purchase Plan, Equity Compensation